Coverage of this story is ongoing.

In news first reported by MSNBC and confirmed by Axios, AstraZeneca plans to announce a deal with the White House to voluntarily align with the Trump Administration’s most-favored-nation (MFN) drug-pricing initiative. This makes them the second biopharmaceutical corporation after Pfizer to agree to lower drug prices in the United States for low-income Americans on Medicaid to those of other wealthy countries. The reduced-price drugs will be available through the TrumpRx.gov website.1-3

Details of the Announcement

In the Oval Office, Pascal Soriot, CEO of AstraZeneca, will meet with President Donald Trump to announce the deal. The United Kingdom-based company follows Pfizer in adhering to Trump’s repeated efforts to get drug companies to comply with his executive actions that seek to reduce domestic drug prices. Trump aims for countries to adhere to MFN drug pricing, ensuring that patients in the US receive medications at the lowest price the company has in any other country across the world.1,3

AstraZeneca will reinforce their commitment to investing $50 billion in manufacturing and research and development in the United States. Recently, they announced an additional $4.5 billion investment in their new manufacturing facility in Virginia. The overall investment is expected to generate thousands of new jobs across the country.1,4,5

Without compliance, the Trump Administration threatened new regulations to force price reductions or the initiation of investigations through the Federal Trade Commission. In July, Trump sent a letter to pharmaceutical companies, including AstraZeneca and Pfizer, encouraging them to adhere to his May executive order centered on MFN. On September 30, Pfizer became the first company to announce a deal with the Trump Administration, at which Trump publicly noted that more deals with other companies would follow.1,4

According to MSNBC, the TrumpRx.gov website will not launch until 2026.1

Pharmacy Times reached out to Office of the Assistant Secretary for Public Affairs at the Department of Health and Human services for comment on the story.

What Pharmacists Should Know

Pharmacies should begin to prepare their staff and core infrastructure for the proliferation of MFN pricing by familiarizing themselves with the government-run drug pricing portal. With this new platform, pharmacies may face direct competition with drug manufacturers for many primary and specialty care drugs. Furthermore, pharmacies should prepare for patients to request price matching to a discounted cash price in the TrumpRx database, risking losing patients if they cannot fulfill the request.6

Until more concrete details of the initiative are announced, pharmacies should prepare for uncertainty and possible price increases if tariffs are leveraged to their fullest extent in response to companies’ participation in the program.6

REFERENCES1. Traylor J. Trump strikes drug-pricing deal with pharma giant AstraZeneca. MSNBC. Published October 10, 2025. Accessed October 10, 2025. https://www.msnbc.com/msnbc/news/trump-strikes-drug-pricing-deal-pharma-giant-astrazeneca-rcna2369052. Bettelheim A, Sullivan P. Trump set to unveil drug price deal with AstraZeneca. Axios. Published October 10, 2025. Accessed October 10, 2025. https://www.axios.com/2025/10/10/trump-drug-prices-astra-zeneca3. Halpern L. Pfizer agrees to lower certain drug prices in the US, aligning with most-favored nation plan. Pharmacy Times. Published October 1, 2025. Accessed October 10, 2025. https://www.pharmacytimes.com/view/pfizer-agrees-to-lower-certain-drug-prices-in-us-aligning-with-most-favored-nation-plan4. AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs. AstraZeneca. News release. Published October 9, 2025. Accessed October 10, 2025. https://www.astrazeneca-us.com/content/az-us/media/press-releases/2025/astrazeneca-plans-to-increase-investment-and-scope-of-its-virginia-manufacturing-facility-to-four-point-five-billion-creating-thirty-six-hundred-new-jobs.html5. AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D. AstraZeneca. News release. Released July 21, 2025. Accessed October 10, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html6. TrumpRx: What pharmacies and plan sponsors need to know. Buchanan. Published October 8, 2025. Accessed October 10, 2025. https://www.bipc.com/trumprx-what-pharmacies-and-plan-sponsors-need-to-know